December 27, 2018

Stemline: A Prospective Bio-tech

Stemline Therapeutics just got FDA approval for its flagship product, Elzonris which will begin selling in 2019.  As a result, analysts have begun raising their targets.  Piper Jarray has a $30 price target.  The company is small and not profitable....yet. 

No comments: